Truist initiated coverage of Centessa (CNTA) with a Buy rating and $30 price target The firm sees “significant upside potential” for ORX750 in Narcolepsy and Idiopathic Hypersomnia, says the analyst, who views orexin-2 receptor agonist’s such as ORX750 as “poised to become the new standard-of-care.” While acknowledging that ORX750 is slightly behind competitors, the analyst thinks the drug has the potential to differentiate on safety, efficacy and dosing convenience.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Positive Market Outlook for Centessa Pharmaceuticals Driven by Promising Developments in Orexin Agonist Class
- Optimistic Buy Rating for Centessa Pharmaceuticals Driven by Orexin Agonist Market Potential and Positive Safety Profile
- Centessa Pharmaceuticals Positioned for Leadership in Orexin Agonist Market with Promising ORX750 Candidate
- Centessa Pharmaceuticals Approves Key Resolutions at AGM
- Centessa Pharmaceuticals Gains FDA Clearance for ORX142 Study